Prevention of Restenosis Following Revascularization
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- José Iglesias, MD
Celgene Corporation
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Uc Davis Medical Center, Ellison Ambulatory Care Center Cardiology Suite 3400
Sacramento, California, United States
- Vascular & Interventional Physicians
Gainsville, Florida, United States
- Midwest Cardiovascular Research Foundation
Davenport, Iowa, United States
- Michigan Vascular Research Center
Flint, Michigan, United States
- Holy Name Hospital
Teaneck, New Jersey, United States
- Lindner Clinical Trials Center
Cincinnati, Ohio, United States
- Rhode Island Hospital
Providence, Rhode Island, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jan 2008
- Primary completion
- 31 Aug 2009
- Completion
- 30 Sept 2009
- Last update posted
- 13 Mar 2012
- Registered enrollment
- 6
- Registry id
- NCT00518284
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.